India Equity Analysis, Reports, Recommendations, Stock Tips and more!
Search Now
Recommendations
Showing posts with label Lupin. Show all posts
Showing posts with label Lupin. Show all posts
Saturday, October 27, 2012
Monday, July 30, 2012
Friday, July 06, 2012
Monday, March 05, 2012
Sunday, February 05, 2012
Wednesday, January 25, 2012
Sunday, November 13, 2011
Wednesday, October 19, 2011
Monday, April 11, 2011
Monday, March 28, 2011
Monday, January 31, 2011
Sunday, January 30, 2011
Sunday, November 07, 2010
Saturday, October 02, 2010
Sunday, July 11, 2010
Lupin
Shareholders can remain invested in the stock of Lupin. Though the stock price has more than doubled since the last ‘buy' recommendation in August 2009, the sustained traction in its formulations exports and an attractive pipeline of products make a reasonable case for remaining invested. That the company has managed to keep up its earnings momentum too provides confidence.
Thursday, June 17, 2010
Saturday, January 23, 2010
Lupin unit gets USFDA nod for Memantine tablets
Lupin announced that its US subsidiary, Lupin Pharmaceuticals, Inc (LPI) has received the tentative approval for the company's Abbreviated New Drug Application (ANDA) for its Memantine Hydrochloride tablets, 5mg and 10mg from the US Food and Drug Administration (USFDA). Lupin's Memantine HCL tablets are AB-rated to Namenda tablets indicated for the treatment of moderate to severe dementia of the Alzheime's type Namenda had annual sales of about US$1.1bn for the twelve months ended September 2009, based on IMS health sales data. Commenting on the approval, Vinita Gupta, Group President & CEO, Lupin Pharmaceuticals Inc. said, "We are pleased to receive this tentative approval and look forward to bringing Memantine HCI tablets to the US market as an affordable generic alternative post-patent expiry".
Sunday, December 20, 2009
Subscribe to:
Posts (Atom)